Suppressive Effects of Procaterol on Expression of IP-10/CXCL 10 and RANTES/CCL 5 by Bronchial Epithelial Cells

被引:0
作者
Ka-Pan Lam
Yu-Te Chu
Chang-Hung Kuo
Wei-Li Wang
Teck-Siang Tok
Yow-Yue Chin
Solomon Chih-Cheng Chen
Chih-Hsing Hung
机构
[1] Pingtung Christian Hospital,Department of Pediatrics
[2] Kaohsiung Medical University Hospital,Departments of Pediatrics
[3] Kaohsiung Municipal Ta-Tung Hospital,Department of Pediatrics
[4] Kaohsiung Medical University,Graduate Institute of Medicine, College of Medicine
[5] Kaohsiung Medical University,Department of Pediatrics, Faculty of Medicine, College of Medicine
来源
Inflammation | 2011年 / 34卷
关键词
bronchial epithelial cells; bronchodilators; CXCL chemokines; CCL chemokines; short acting β2 agonist;
D O I
暂无
中图分类号
学科分类号
摘要
As indicated in the Global Initiative for Asthma guidelines, short-acting β2-adrenoreceptor agonists (SABAs) are important relievers in asthma exacerbation. Interferon γ-inducible protein (IP)-10/CXCL 10 is a T-helper type 1 (Th1) cell-related chemokine which is important in the recruitment of Th1 cells involved in host immune defense against intracellular pathogens such as viral infection. Regulated on activation, normal T expressed and secreted (RANTES)/CCL 5 is a chemokine which plays a role in attractant of eosinophils, mast cells, and basophils toward the site of allergic inflammation. Bronchial epithelial cells are first-line barriers against pathogen invasion. However, whether SABAs have regulatory effects on the expression of IP-10 and RANTES in bronchial epithelial cells is unknown. BEAS-2B cells, the human bronchial epithelial cell lines, were pretreated with procaterol (one of the SABAs) or dibutyryl-cAMP (a cyclic AMP analog) at different doses for 1 h and then stimulated with poly I:C (10 μg/mL). Supernatants were collected 12 and 24 h after poly I:C stimulation to determine the concentrations of IP-10 and RANTES by ELISA. In some cases, the cells were pretreated with selective β2-adrenoreceptor antagonist, ICI-118551, 30 min before procaterol treatment. To investigate the intracellular signaling, the cells were pretreated with mitogen-activated protein kinase (MAPK) inhibitors and a NF-κB inhibitor 30 min before procaterol treatment. Western blot was also used to explore the intracellular signaling. Procaterol significantly suppressed poly I:C-induced IP-10 and RANTES in BEAS-2B cells in a dose-dependent manner. ICI-118551, a selective β2-adrenoreceptor antagonist, could significantly reverse the suppressive effects. Dibutyryl-cAMP could confer the similar effects of procaterol on poly I:C-induced IP-10 and RANTES expression. Data of Western blot revealed that poly I:C-induced p-ERK, p-JNK, and pp38 expression, but not pp65, were suppressed by procaterol. SABAs could suppress poly I:C-induced IP-10 and RANTES expression in bronchial epithelial cells, at least in part, via β2-adrenoreceptor-cAMP and MAPK-ERK, JNK, and p38 pathways.
引用
收藏
页码:238 / 246
页数:8
相关论文
共 141 条
  • [1] van Aalderen WM(1999)Is childhood asthma an inflammatory disease? Allergy 54 62-67
  • [2] Sprikkelman AB(2007)T-cell responses to allergens The Journal of Allergy and Clinical Immunology 119 280-294
  • [3] Hoekstra MO(1998)Inflammatory mediators of asthma: An update Pharmacological Reviews 50 515-596
  • [4] Woodfolk JA(2007)Mechanisms of allergen-specific immunotherapy The Journal of Allergy and Clinical Immunology 119 780-789
  • [5] Barnes PJ(2006)Mechanisms of airway hyperresponsiveness The Journal of Allergy and Clinical Immunology 118 551-559
  • [6] Chung KF(2007)Eosinophil trafficking in allergy and asthma The Journal of Allergy and Clinical Immunology 119 1303-1310
  • [7] Page CP(2004)Defense mechanisms against influenza virus infection in the respiratory tract mucosa Japanese Journal of Infectious Diseases 57 236-247
  • [8] Akdis M(2003)Chemokines: Roles in leukocyte development, trafficking, and effector function The Journal of Allergy and Clinical Immunology 111 1185-1199
  • [9] Akdis CA(2003)Chemokines in asthma: Cooperative between chemokines & IL-13 The Journal of Allergy and Clinical Immunology 111 227-242
  • [10] Cockcroft DW(2001)Asthma The New England Journal of Medicine 344 350-362